ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1156

Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry

Jessica Walsh1, Kelley Myers2, Carol Mansfield2, William Tillett3, Peter Nash4, Colton Leach2, William Nowell5, Kelly Gavigan5, Patrick Zueger6, Erin McDearmon-Blondell7 and Alexis Ogdie-Beatty8, 1Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 2RTI Health Solutions, Research Triangle Park, NC, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Griffith University, Brisbane, Australia, 5Global Healthy Living Foundation, Upper Nyack, NY, 6AbbVie Inc., Mettawa, IL, 7AbbVie Inc., Elmhurst, IL, 8University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: Biologicals, Patient reported outcomes, Psoriatic arthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: To optimize patient-provider shared decision-making, it is important to understand patients’ experience with psoriatic arthritis (PsA) and its treatment, including how treatment experience may impact their preferences. We evaluated PsA symptom burden, the most important impacts of disease, and therapy preferences based on past biologic disease-modifying antirheumatic drug (bDMARD) experience among PsA patients from the ArthritisPower registry.

Methods: A cross-sectional, web-based survey was developed and administered to adults with a self-reported diagnosis of PsA recruited from a United States rheumatology patient-centered research registry, ArthritisPower. Object case best-worst scaling (BWS) was used to evaluate the relative burden of 11 PsA symptoms and the relative importance of improvement in 9 PsA-related disease impacts. BWS data were analyzed using a random parameters logit model stratified by past bDMARD experience. Additional survey questions and analyses assessed the impact of prior treatment experience on patients’ experience with methotrexate (MTX) and preference for mode of treatment administration as well as overall treatment satisfaction.

Results: Among 332 respondents, 74 (22.3%) were bDMARD-naïve and 258 (77.7%) were bDMARD-experienced. In both groups, musculoskeletal pain-related symptoms were reported as most bothersome while the least bothersome symptoms were psoriasis-related (Figure 1). Patients who were bDMARD-naïve rated morning stiffness as more bothersome than bDMARD-experienced patients. The ability to perform physical activities was reported as the most important disease impact to improve by both groups, while bDMARD-naïve patients rated improvement in sleep quality as more important compared to bDMARD-experienced patients (Figure 2). Among patients with MTX experience, a similar proportion of bDMARD-naïve patients (40%) and bDMARD-experienced patients (34%) were satisfied with MTX. A significantly greater proportion of bDMARD-naïve patients felt that mode of administration was an important factor when deciding to start a new therapy compared to bDMARD-experienced patients (57% vs. 42%, p< 0.05). When asked to choose among four different ways of taking their PsA medication (oral once or twice per day, injection every 2 weeks or every month), a once daily oral tablet was the most commonly chosen mode by both bDMARD-naïve (39%) and -experienced patients (38%). Overall satisfaction with current treatment was higher among patients taking an advanced therapy (bDMARDs or tofacitinib) compared with those taking conventional DMARDs only (72% vs 39%, p< 0.05).

Conclusion: Among patients with PsA, musculoskeletal pain-related symptoms were ranked as most bothersome, and improvements in physical function were ranked as most important, regardless of bDMARD treatment experience. Though mode of administration was rated as more important among bDMARD-naïve patients, both bDMARD-naïve and -experienced patients preferred a once daily oral route of administration. These findings may serve to optimize patient-provider treatment discussion and decision making across PsA patient populations.

Figure 1. Relative Burden of PsA Symptoms by Biologic Treatment Experience

Figure 2. Relative Importance of Improving PsA Disease Impacts by Biologic Treatment Experience


Disclosures: J. Walsh, AbbVie, 2, 5, Merck, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Eli Lilly, 1, 2, Novartis, 2, 5, Amgen, 2, 5; K. Myers, RTI Health Solutions, 3; C. Mansfield, RTI Health Solutions, 3; W. Tillett, AbbVie, 1, 2, 6, Amgen, 1, 2, 6, Celgene, 1, 2, 6, Eli Lilly, 1, 2, 6, Janssen, 1, 2, 6, Novartis, 1, 2, 6, MSD, 1, 2, 6, Pfizer, 1, 2, 6, UCB, 1, 2, 6, Merck Sharp & Dohme, 2; P. Nash, Janssen, 2, 5, 6, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Novartis, 2, 5, 6, Eli Lilly, 2, 5, 6, Roche, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Sanofi, 2, 5, 6, Merck, 2, 5, 6, UCB, 2, 5, 6, Gilead/Galapagos, 2, 5, 6, Celgene, 2, 5, 6, Samsung, 2, 5, 6; C. Leach, RTI Health Solutions, 3; W. Nowell, Global Healthy Living Foundation, 3, AbbVie, 5, Amgen, 5, Eli Lilly, 5; K. Gavigan, Global Healthy Living Foundation, 3; P. Zueger, AbbVie, 3, 11; E. McDearmon-Blondell, AbbVie, 3, 11; A. Ogdie-Beatty, AbbVie, 2, Amgen, 2, 5, BMS, 2, Celgene, 2, CorEvitas (formerly Corrona), 2, Janssen, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 5, Rheumatology Research Foundation, 5, National Psoriasis Foundation, 5, Pfizer (to University of Pennsylvania), 5, AbbVie (to University of Pennsylvania), 5, Novartis (to University of Pennsylvania), 5, Gilead, 2.

To cite this abstract in AMA style:

Walsh J, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell W, Gavigan K, Zueger P, McDearmon-Blondell E, Ogdie-Beatty A. Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impact-of-treatment-experience-on-patient-preferences-and-disease-burden-in-psoriatic-arthritis-results-from-a-rheumatology-patient-research-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-treatment-experience-on-patient-preferences-and-disease-burden-in-psoriatic-arthritis-results-from-a-rheumatology-patient-research-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology